Welcome to our dedicated page for Intercept Pharmaceuticals news (Ticker: ICPT), a resource for investors and traders seeking the latest updates and insights on Intercept Pharmaceuticals stock.
Intercept Pharmaceuticals, Inc. (ICPT) is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics aimed at treating progressive, non-viral liver diseases. Intercept's core focus is primarily on conditions such as primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and biliary atresia. With its headquarters in New York and additional offices in San Diego, London, and Perugia, Intercept is well-positioned globally to drive forward its ambitious healthcare initiatives.
The company's flagship product, Ocaliva® (obeticholic acid), is a farnesoid X receptor (FXR) agonist, approved for the treatment of adults with PBC, either in combination with ursodeoxycholic acid (UDCA) for those with an inadequate response to UDCA or as monotherapy for patients who cannot tolerate UDCA. The recent developments include a landmark Phase 3 POISE trial revealing significant impacts on key biomarkers for PBC treatment, demonstrating Ocaliva's potential to not only reduce gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) levels but also improve clinical outcomes.
In addition, Intercept is actively engaged in advancing the investigational combination of OCA and bezafibrate, shown in Phase 2 studies to affect multiple key serum biomarkers predictive of clinical outcomes. This combination therapy targets both FXR and peroxisome proliferator-activated receptor (PPAR) pathways, offering potential enhanced therapeutic benefits.
Financially stable, Intercept continues to invest significantly in R&D, highlighted by recent presentations at the American Association for the Study of Liver Diseases (AASLD) and Digestive Disease Week® (DDW). As of February 2024, the FDA has accepted a supplemental New Drug Application (sNDA) for Ocaliva, further solidifying its position in the liver disease treatment market. Intercept remains committed to improving patient outcomes and enhancing the quality of life for those affected by these serious conditions.
For the most current news and developments, visit the Intercept Pharmaceuticals website or follow their updates on LinkedIn and Twitter.
Intercept Pharmaceuticals, a biopharmaceutical company, will present five abstracts on primary biliary cholangitis at Digestive Disease Week® 2024. Highlights include data from Phase 2 and Phase 3 trials evaluating obeticholic acid. The company aims to showcase its commitment to improving the lives of those with PBC and share insights with the scientific community.
FAQ
What is the market cap of Intercept Pharmaceuticals (ICPT)?
What does Intercept Pharmaceuticals, Inc. specialize in?
What is Ocaliva® (obeticholic acid)?
Where are Intercept Pharmaceuticals’ offices located?
What are the recent developments at Intercept Pharmaceuticals?
How does Intercept Pharmaceuticals contribute to liver disease treatment?
What is the significance of the POISE trial?
What is the investigational combination of OCA and bezafibrate?
How does Intercept Pharmaceuticals stay committed to its mission?
What are the safety concerns associated with Ocaliva?
Where can I find more information about Intercept Pharmaceuticals?
